Recombinant human IL-17A protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human IL-17A protein - Mammalian cell-expressed, tag-free, carrier-free

Recombinant human IL-17A is a high-quality and biologically active cytokine, validated using proprietary IL-17 reporter cells. This pro-inflammatory cytokine is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.

Recombinant human IL-17A can be used together with HEK-Blue™ IL-17 cells for the screening of inhibitory molecules, such as Secukinumab, a therapeutic monoclonal antibody targeting IL-17A (see figures).

 

Key features

  • Each lot is validated using HEK-Blue™ IL-17 cells
  • Endotoxin ≤ 0.001 EU/µg
  • 0.2 µm sterile-filtered

Applications

  • Standard for IL-17A detection and quantification
  • Screening and release assays for antibodies blocking IL-17A signaling
  • Screening and release assays for engineered IL-17

 

The interleukin-17 (IL-17) family comprises six members (IL-17A – 17F), which have various biological functions, including driving an inflammatory cascade during infections and autoimmune diseases. IL-17A is a key therapeutic target for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

IL-17A signaling and biological functions
IL-17A signaling and biological functions

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Synonyms
Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8)
Accession sequence

Q16552

Protein size
132 a.a. (G24-A155)
Molecular weight
~ 16 kDa (SDS-PAGE)
Carrier
Carrier-free
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), with glycine, saccharose, and stabilizing agents

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.2 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human IL-17A
  • Cat code: 
    rcyc-hil17a
  • Quantity: 
    20 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 6 months

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

IL-17A background

Interleukin 17 (IL-17) is a family of six closely related cytokines (IL-17A to IL-17F) which have both pro-inflammatory and anti-inflammatory activities. IL-17A and IL-17F, which can form a heterodimer, play an important role in Th17 immunity and are implicated in tumorigenesis and autoimmune diseases, whereas IL-17E (also known as IL-25) appears to promote Th2 immunity [1,2]. Interleukin‑17A (IL‑17A), also known as CTLA‑8, is a 15‑20 kDa glycosylated cytokine that plays an important role in anti‑microbial and chronic inflammation. It induces chemokine production, neutrophil influx, and the production of antibacterial peptides [3].

IL-17 cytokines exert their biological activities by binding to heterodimeric receptors containing the ubiquitous IL-17RA chain and a second IL-17R(C, B, or E) chain. IL-17A and IL-17F bind to the IL-17RA/IL-17RC receptor, IL-17C binds to the IL-17RA/IL-17RE receptor, and IL-17E binds to the IL-17RA/IL-17RB receptor [1, 2]. The activated heterodimeric receptor recruits the Act1 adaptor and induces the TNF receptor-associated factor 6 (TRAF6) ubiquitylation. This triggers a signaling cascade that results in NF-κB and AP-1 activation [1].

Antibodies targeting IL-17A, namely Secukinumab and Ixekizumab, were approved in 2016 for the treatment of moderate-to-severe plaque psoriasis, ankylosing spondylitis (AS), and psoriatic arthritis (PsA). Surprisingly, trials of Secukinumab and Brodalumab, an anti-IL-17RA in Crohn’s disease, were terminated early due to worsening of the disease in the treatment group [3-4]. These findings agree with IL-17's supportive role in skin wound healing [3].

 

References:

1. Monin L. & Gaffen S.L., 2018. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 10(4).
2. Pappu R. et al., 2011. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 134: 8-16.
3. Huangfu L, Li R, Huang Y, Wang S, 2023. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther.11;8(1):402.
4. Amatya N, Garg AV, Gaffen SL, 2017. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 38(5):310-322.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?